Patents by Inventor Ding-Quan Qian

Ding-Quan Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20210395246
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: January 28, 2021
    Publication date: December 23, 2021
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang
  • BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20210238168
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: April 13, 2021
    Publication date: August 5, 2021
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 11014923
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: May 25, 2021
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20210139485
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 22, 2020
    Publication date: May 13, 2021
    Inventors: Xiaozhao Wang, Pei Gan, Heeoon Han, Taisheng Huang, Matthew S. McCammant, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11001571
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: May 11, 2021
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20210107901
    Abstract: The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 15, 2021
    Inventors: Yingda Ye, Zhenwu Li, Ding-Quan Qian, Sarah Winterton, Kaijiong Xiao, Liangxing Wu, Wenqing Yao, Joshua Hummel, Meizhong Xu, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210107900
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: August 18, 2020
    Publication date: April 15, 2021
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 10947230
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: March 16, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yaping Sun, Wenqing Yao, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Fenglei Zhang
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20210032244
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: June 9, 2020
    Publication date: February 4, 2021
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Ding-Quan Qian, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20210024487
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: May 1, 2020
    Publication date: January 28, 2021
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Leah C. Konkol, Ding-Quan Qian, Bo Shen, Wenqing Yao, Fenglei Zhang
  • PYRAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS
    Publication number: 20210017156
    Abstract: The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: March 4, 2020
    Publication date: January 21, 2021
    Inventors: Joshua Hummel, Jingwei Li, Zhenwu Li, Ding-Quan Qian, Liangxing Wu, Kaijiong Xiao, Meizhong Xu, Jeffrey C. Yang, Wenqing Yao, Fenglei Zhang, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210017164
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 21, 2021
    Inventors: Liang Lu, Ding-Quan Qian, Liangxing Wu, Wenqing Yao
  • IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE
    Publication number: 20200397893
    Abstract: Compositions and methods for inducing PD-L1 internalization are disclosed. The methods include reducing the amount of cell surface PD-L1 by contacting a cell expressing PD-L1 with a compound that binds to cell surface PD-L1 and induces PD-L1 internalization. Compounds that induce PD-L1 internalization can be used to enhance, stimulate and/or increase an immune response and treat a PD-1-related disease or condition.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 24, 2020
    Inventors: Phillip C. Liu, Alla Volgina, Richard Wynn, Nina Zolotarjova, Liangxing Wu, Kaijiong Xiao, Song Mei, Liang Lu, Wenyu Zhu, Yingda Ye, Haisheng Wang, Ding-Quan Qian, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20200399267
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Application
    Filed: July 9, 2020
    Publication date: December 24, 2020
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
    Publication number: 20200377504
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: April 7, 2020
    Publication date: December 3, 2020
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Yaping Sun, Liang Lu, Ding-Quan Qian, Meizhong Xu, Jincong Zhuo, Wenqing Yao
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 10851105
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: December 1, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Liang Lu, Ding-Quan Qian, Bo Shen, Wenqing Yao
  • Immunomodulator compounds and methods of use
    Patent number: 10806785
    Abstract: Compositions and methods for inducing PD-L1 internalization are disclosed. The methods include reducing the amount of cell surface PD-L1 by contacting a cell expressing PD-L1 with a compound that binds to cell surface PD-L1 and induces PD-L1 internalization. Compounds that induce PD-L1 internalization can be used to enhance, stimulate and/or increase an immune response and treat a PD-1-related disease or condition.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: October 20, 2020
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Wenyu Zhu, Ding-Quan Qian, Kaijiong Xiao
  • Heterocyclic compounds as immunomodulators
    Patent number: 10800768
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: October 13, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Jingwei Li, Wenqing Yao, Chao Qi, Ding-Quan Qian, Fenglei Zhang
  • Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors
    Publication number: 20200317680
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 8, 2020
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Imidazotriaines and imidazopyrimidines as kinase inhibitors
    Patent number: 10738052
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 11, 2020
    Assignees: INCYTE HOLDINGS CORPORATION, INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao